



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

VX-765

Catalog #: 27779-3

Lot #: 220708

Size: 50 mg


Structure:

CAS Registry #: 273404-37-8

Purity: ≥96%

Chemical Formula: C₂₄H₃₃ClN₄O₆

Molecular Weight: 508.99 Da



Description: VX-765 is a novel Caspase-1 inhibitor being investigated for the treatment of epilepsy.

Synonym(s): VX-765; VX765; Belnacasan; (2S)-1-[(2S)-2-[(4-amino-3-chlorobenzoyl)amino]-3,3-dimethylbutanoyl]-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]pyrrolidine-2-carboxamide

Appearance: White crystalline powder

Solubility: Insoluble in H₂O; ≥313 mg/mL in DMSO; ≥50.5 mg/mL in EtOH with ultrasonic

Storage/Stability: Store desiccated at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.

Warnings: Protect from moisture.

References:

1. Boxer MB, et al. ChemMedChem. 2010 May 3;5(5):730-8.
2. Wannamaker W, et al. J Pharmacol Exp Ther. 2007 May;321(2):509-16.